Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed 6 months of treatment with the study drug and the Month 6 visit in the core study NCT00537082.~* Females of childbearing potential who have a negative pregnancy test in the core study NCT00537082.~Exclusion Criteria:~* Patients who permanently discontinued study drug treatment prior to the Month 6 visit in the core study NCT00537082.~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod 0.5 mg (Type: EXPERIMENTAL): Patients who received fingolimod 0.5 orally once daily in the core study continued on the same dose in this extension study.
- Fingolimod 1.25 mg (Type: EXPERIMENTAL): Patients who received fingolimod 1.25 mg orally once daily in the core study continued on the same dose in this extension study.
- Placebo-fingolimod (Type: EXPERIMENTAL): Patients who were randomized to placebo in the core study were re-randomized to either fingolimod 0.5 or 1.25 mg (1:1) orally once daily in this extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).